High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients

European Journal of Haematology

Volumn 80, Issue 4, 2008, Pages 310-317

  Mylin, Anne K ^a   Abildgaard, Niels ^b   Johansen, Julia S ^a   Andersen, Niels F ^c   Heickendorff, Lene ^c   Standal, Therese ^d   Gimsing, Peter ^a   Knudsen, Lene M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Bone disease; Chitinase 3 like 1; Human cartilage glycoprotein 39; Multiple myeloma; YKL 40

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN GP 39; MELPHALAN; MITOXANTRONE; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; PYRIDINOLINE; UNCLASSIFIED DRUG; VINCRISTINE; YKL 40 PROTEIN;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METABOLISM; BONE RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; X RAY ANALYSIS;

EID: 40449134510     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01027.x     Document Type: Article

References (29)

1. 1 Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 ; 78: 21–33.
2. 2 Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989 ; 7: 1909–14.
3. 3 Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005 ; 16: 1223–31.
4. 4 Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt‐signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003 ; 349: 2483–94.
5. 5 Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell‐cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004 ; 104: 2484–91.
6. 6 Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Norgaard PH, Lenhoff S, Dahl IM, Johnsen HE. Serum YKL‐40 concentrations in newly diagnosed multiple myeloma patients and YKL‐40 expression in malignant plasma cells. Eur J Haematol 2006 ; 77: 416–24.
7. 7 Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL‐40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006 ; 15: 194–202.
8. 8 Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL‐40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005 ; 96: 183–90.
9. 9 Nigro JM, Misra A, Zhang L, et al. Integrated array‐ comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005 ; 65: 1678–86.
10. 10 Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase‐like lectin, YKL‐40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006 ; 281: 21082–95.
11. 11 De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL‐40 (cartilage gp‐39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001 ; 285: 926–31.
12. 12 Jacques C, Recklies AD, Levy A, Berenbaum F. HC‐gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions. Osteoarthritis Cartilage 2007 ; 15: 138–46.
13. 13 Recklies AD, White C, Ling H. The chitinase 3‐like protein human cartilage glycoprotein 39 (HC‐gp39) stimulates proliferation of human connective‐tissue cells and activates both extracellular signal‐regulated kinase‐ and protein kinase B‐mediated signalling pathways. Biochem J 2002 ; 365 (Pt 1): 119–26.
14. 14 Ling H, Recklies AD. The chitinase 3‐like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin‐1 and tumour necrosis factor‐alpha. Biochem J 2004 ; 380 (Pt 3): 651–9.
15. 15 Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, Ford J, Kandra A. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial. Danish‐Swedish co‐operative study group. Br J Haematol 1998 ; 101: 280–6.
16. 16 Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre‐treatment levels of S‐ICTP and U‐Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003 ; 120: 235–42.
17. 17 Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high‐dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998 ; 102: 1115–23.
18. 18 Harvey S, Weisman M, O’Dell J, Scott T, Krusemeier M, Visor J, Swindlehurst C. Chondrex: new marker of joint disease. Clin Chem 1998 ; 44: 509–16.
19. 19 Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004 ; 89: 567–77.
20. 20 Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL‐40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995 ; 31A: 1437–42.
21. 21 Johansen JS, Kirwan JR, Price PA, Sharif M. Serum YKL‐40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand J Rheumatol 2001 ; 30: 297–304.
22. 22 Matsumoto T, Tsurumoto T. Serum YKL‐40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001 ; 19: 655–60.
23. 23 Stoffel K, Engler H, Kuster M, Riesen W. Changes in biochemical markers after lower limb fractures. Clin Chem 2007 ; 53: 131–4.
24. 24 Abildgaard N, Glerup H, Rungby J, Bendix‐Hansen K, Kassem M, Brixen K, Heickendorff L, Nielsen JL, Eriksen EF. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000 ; 64: 121–9.
25. 25 Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate‐binding properties of the human cartilage glycoprotein‐39. J Biol Chem 2003 ; 278: 37753–60.
26. 26 Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992 ; 7: 501–12.
27. 27 Johansen JS, Hoyer PE, Larsen LA, Price PA, Mollgard K. YKL‐40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007 ; 55: 1213–28.
28. 28 Connor JR, Dodds RA, Emery JG, Kirkpatrick RB, Rosenberg M, Gowen M. Human cartilage glycoprotein 39 (HC gp‐39) mRNA expression in adult and fetal chondrocytes, osteoblasts and osteocytes by in‐situ hybridization. Osteoarthritis Cartilage 2000 ; 8: 87–95.
29. 29 Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev‐Petersen K, Lorenzen I, Price PA. Serum YKL‐40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999 ; 38: 618–26.